60 studies found for:    anti-EGFR antibodies
Show Display Options
Rank Status Study
1 Recruiting BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Condition: Cancer
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Drug: Panitumumab;   Drug: 5-fluorouracil
2 Recruiting Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer
Conditions: Neoplasm Metastasis;   Gastric Cancer;   Colorectal Cancer
Intervention: Biological: GC1118
3 Completed
Has Results
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
Condition: Colorectal Cancer
Intervention: Drug: Everolimus (RAD001)
4 Recruiting Treatment Optimization of Cetuximab in Patients With Metastatic Colorectal Cancer Based on Tumor Uptake of 89Zr-labeled Cetuximab Assessed by PET
Condition: Colorectal Cancer
Intervention: Behavioral: pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles
5 Not yet recruiting Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions: Carcinoma, Squamous Cell of Head and Neck;   Head Neck Cancer Squamous Cell Recurrent;   Head Neck Cancer Squamous Cell Metastatic
Interventions: Drug: Ficlatuzumab;   Drug: Cetuximab
6 Unknown  Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment
Conditions: Colorectal Cancer;   Skin Toxicities
Intervention:
7 Terminated Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
Condition: Head and Neck Cancer
Interventions: Biological: cetuximab;   Procedure: conventional surgery;   Radiation: radiation therapy
8 Withdrawn Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
Condition: Head and Neck Cancer
Interventions: Biological: panitumumab;   Drug: cisplatin;   Drug: fluorouracil;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: quality-of-life assessment;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
9 Completed
Has Results
Zalutumumab in Patients With Non-curable Head and Neck Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Cancer
Interventions: Drug: Zalutumumab;   Other: Control
10 Recruiting Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Conditions: Epidermoid Carcinoma;   Anus
Interventions: Drug: radiochemotherapy;   Drug: Panitumumab
11 Completed Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Irinotecan;   Biological: Cetuximab;   Biological: RAD001
12 Completed Nimotuzumab in Children With Intrinsic Pontine Glioma
Condition: Diffuse Instrinsic Ponitine Glioma
Intervention: Drug: nimotuzumab
13 Recruiting Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal
Condition: Carcinoma of Anal Canal
Interventions: Radiation: RADIOTHERAPY;   Biological: PANITUMUMAB;   Drug: MITOMYCIN;   Drug: CAPECITABINE
14 Recruiting Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects
Conditions: Colorectal Cancer Metastatic;   C-met Overexpression
Intervention: Drug: Tivantinib (ARQ197)
15 Completed Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms
Condition: Upper Gingival Squamous Cell Carcinoma
Intervention: Other: Blood sample for identifying the polymorphism
16 Active, not recruiting Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer
Condition: Ras-wildtype Colorectal Cancer
Interventions: Drug: Erythromycin;   Drug: Doxycycline
17 Recruiting Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure
Conditions: Colorectal Cancer;   Liver Metastases
Interventions: Drug: oxaliplatin;   Drug: raltitrexed;   Drug: other intravenous chemotherapy drugs
18 Terminated Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer
Conditions: Head and Neck Neoplasms;   Laryngeal Neoplasms;   Mouth Neoplasms;   Pharyngeal Neoplasms
Interventions: Drug: cetuximab;   Drug: cisplatin (associated to radiotherapy)
19 Recruiting COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Other: Blood analysis by EPISPOT and Cellsearch
20 Unknown  Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
Condition: Prostate Cancer
Interventions: Drug: etoposide;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years